Biomaterials 2017 Mar;121:130-143 PMID:28088075

Liu H,Xie Y,Zhang Y,Cai Y,Li B,Mao H,Liu Y,Lu J,Zhang L,Yu R

Brain Hospital, Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China; Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, PR China. Electronic address: yu.rutong@163.com.

Chemoradiotherapy; Doxorubicin; Glioma; Liposomes; Radiation-Sensitizing Agents; Tumor Hypoxia

The treatment of malignant primary brain tumors is challenging. Concomitant radiochemotherapy has become the standard clinical treatment for malignant glioma, but there are two critical challenges to overcome in order to increase efficacy. First, glioma is known to have increased resistant to radiation due to its intra-tumoral hypoxia. In addition, the blood-brain barrier (BBB) restricts the distribution of the chemotherapeutic agent to the brain. Therefore, we developed a hypoxic radiosensitizer-prodrug liposome (MLP), in order to deliver DOX to the tumor and to overcome the above challenges, achieving a synergistic chemo-/radiotherapy treatment of malignant glioma. In this study, hypoxic radiosensitizer nitroimidazoles were conjugated with lipid molecules with a hydrolysable ester bond to form MDH. MDH was mixed together with DSPE-PEG2000 and cholesterol to make MLP liposomes, which were found to have strong radiosensitivity and to promote cargo release under hypoxic conditions, due to the properties of nitroimidazoles under hypoxic conditions. MLP/DOX was found to have distinct advantages, including precise and stealthy pharmacokinetics and efficient passive uptake by the tumor. Furthermore, the combination of MLP/DOX and radiotherapy (RT) significantly inhibited glioma growth as assessed by invivo bioluminescence imaging. These findings suggest that MLP is a promising candidate as a DOX delivery system to enhance the antitumor treatment effects on glioma, owing to synergistic chemo-/radiotherapy.